Low-dose SAHA enhances CD8⁺ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is a highly aggressive type of lung cancer with poor responses to traditional therapies such as surgery, radiotherapy, and chemotherapy. While immunotherapy has become an effective approach for treating multiple types of cancer, solid tumors frequently exhibit immune escape through various mechanisms, including downregulation of MHC I expression. However, whether the upregulation of MHC I expression can improve the immunotherapeutic effect on NSCLC remains unexplored. Suberoylanilide hydroxamic acid (SAHA) is a potent histone deacetylase (HDAC) inhibitor that has been applied clinically to treat lymphoma, but a high dose of SAHA kills tumor cells and normal cells without preference. Here, we report that low-dose SAHA enhances CD8^+<

SUBMITTER: Dong W 

PROVIDER: S-EPMC11850570 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature